Mather Group’s Corcept Therapeutics CORT Stock Holding History

Mather Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.42K	Buy	+47	New	+$5.06K	﹤0.01%	1799

Other funds holding CORT

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Mather Group's CORT Position: Q3 2026 in Review

Mather Group opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 47 shares worth $5.42K. The stake represents ﹤0.01% of the portfolio and ranks #1799 among its holdings.

84 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

Mather Group held 47 shares of Corcept Therapeutics worth $5.42K as of Q3 2026.
Corcept Therapeutics was a new Mather Group position in Q3 2026.
Corcept Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1799 holding.
84 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.